This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Unit Dose Budesonide
Drug Names(s): UDB, MAP0010
Description: UDB is an inhaled corticosteroid, developed using MAP's proprietary technology, that is designed to be administered more quickly and to provide efficacy at a lower dose than the conventional nebulized corticosteroid currently on the market in the United States.
In December 2008, AstraZeneca and MAP Pharmaceuticals announced an exclusive worldwide agreement to develop and commercialize Unit Dose Budesonide (UDB).
Under the terms of the agreement, AstraZeneca will pay MAP Pharmaceuticals an upfront cash payment of $40 million and an additional $35 million upon the successful achievement of primary endpoint and safety results in the currently ongoing Phase III clinical study. In addition, upon the occurrence of certain events and conditions, MAP Pharmaceuticals is eligible to receive up to $240 million in other potential development and regulatory milestones. The agreement also provides for additional progressively demanding sales performance-related milestone payments of up to $585 million in the event the product is a considerable commercial success.
AstraZeneca also will support and fund the establishment of a MAP Pharmaceuticals sales force to co-promote UDB in the United States for a certain period of time after product...See full deal structure in Biomedtracker
Unit Dose Budesonide News
Additional information available to subscribers only: